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Impaired NK Cell Responses to Pertussis and H1N1 Influenza
Vaccine Antigens in Human Cytomegalovirus-Infected
Individuals
Carolyn M. Nielsen,* Matthew J. White,* Christian Bottomley,† Chiara Lusa,*
Ana Rodrı´guez-Gala´n,* Scarlett E. G. Turner,* Martin R. Goodier,* and Eleanor M. Riley*
NK cells contribute to postvaccination immune responses after activation by IL-2 from Ag-specific memory T cells or by cross-
linking of the low-affinity IgG receptor, CD16, by Ag–Ab immune complexes. Sensitivity of NK cells to these signals from the
adaptive immune system is heterogeneous and influenced by their stage of differentiation. CD56dimCD57+ NK cells are less
responsive to IL-2 and produce less IFN-g in response to T cell–mediated activation than do CD56bright or CD56dimCD572 NK
cells. Conversely, NK cell cytotoxicity, as measured by degranulation, is maintained across the CD56dim subsets. Human CMV
(HCMV), a highly prevalent herpes virus causing lifelong, usually latent, infections, drives the expansion of the CD56dimCD57+
NKG2C+ NK cell population, skewing the NK cell repertoire in favor of cytotoxic responses at the expense of cytokine-driven
responses. We hypothesized, therefore, that HCMV seropositivity would be associated with altered NK cell responses to vaccine
Ags. In a cross-sectional study of 152 U.K. adults, with HCMV seroprevalence rate of 36%, we find that HCMV seropositivity is
associated with lower NK cell IFN-g production and degranulation after in vitro restimulation with pertussis or H1N1 influenza
vaccine Ags. Higher expression of CD57/NKG2C and lower expression of IL-18Ra on NK cells from HCMV seropositive subjects
do not fully explain these impaired responses, which are likely the result of multiple receptor–ligand interactions. This study
demonstrates for the first time, to our knowledge, that HCMV serostatus influences NK cell contributions to adaptive immunity
and raises important questions regarding the impact of HCMV infection on vaccine efficacy. The Journal of Immunology, 2015,
194: 4657–4667.
N
atural killer cells are traditionally classified as cells
of the innate immune system but can also act as media-
tors of adaptive immunity. In addition to their well-
recognized role in Ab-dependent cytotoxicity (ADCC), recent
research has demonstrated a potential contribution to adaptive
responses through their activation by Ag-specific CD4+ T cell–
derived IL-2 (1–7). The heightened IFN-g response of NK cells in
the context of a vaccine recall response suggests that NK cells
may play a role in protection from vaccine-preventable diseases,
particularly as NK cells respond more quickly than T cells and
comprise as much as 70% of all IFN-g–producing cells in the first
12–24 h of the recall response (3).
We have shown, using the individual components of the diph-
theria toxoid/tetanus toxoid/whole-cell pertussis vaccine, that
activation of NK cells after restimulation with vaccine Ags is
heterogeneous, with CD56bright and CD56dimCD572 NK cells
being most responsive as measured by surface expression of the
high-affinity IL-2 receptor (CD25) and accumulation of intracel-
lular IFN-g (CD25+IFN-g+) (6). Expression of CD57 by CD56dim
NK cells was associated with a reduced capacity to produce IFN-g,
although degranulation responses were maintained (6). These
data are consistent with the accepted model of NK cell maturation
whereby acquisition of CD57 is a marker of decreased sensitivity
to exogenous cytokine stimulation (8, 9).
Human CMV (HCMV) infection drives profound changes in
the NK cell repertoire. In particular, HCMV infection is strongly
associated with preferential expansion of the CD56dimCD57+
NKG2C+ NK cell subset (10–12). This has direct implications for
NK cell function as CD56dimCD57+NKG2C+ NK cells degranu-
late and secrete cytokines such as IFN-g and TNF-a in response to
cross-linking of CD16 (by IgG) or natural cytotoxicity receptors
(by infected, stressed, or transformed cells) but respond poorly to
proinflammatory cytokines such as IL-12 and IL-18 (12, 13).
These observations imply that, in the context of infection or
vaccination, NK cells from HCMV-seropositive (HCMV+) indi-
viduals may effectively mediate ADCC after cross-linking of
CD16 by IgG in immune complexes (11, 13, 14), but may respond
poorly to inflammatory cytokines (reviewed in Ref. 15). Specifi-
cally, the expanded CD56dimCD57+NKG2C+ NK cell subset may
be less sensitive to IL-2 produced by Ag-specific CD4+ T cells and
IL-12/IL-18 from accessory cells, such as dendritic cells and
macrophages (3, 6). However, much of the data on skewing of the
NK cell repertoire in HCMV+ individuals comes from studies of
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hematopoietic stem cell or solid organ transplantation (11, 16, 17),
and follow-up of these patients over time, in terms of susceptibility
to infection or response to vaccination, is lacking. As a result, the
true functional significance of HCMV-driven NK cell phenotypic
changes is poorly understood. Moreover, previous investigations of
the impact of HCMV infection on vaccination have produced rather
inconsistent results, with some studies reporting impaired vaccine
responses in HCMV+ donors (18–23), whereas others find no im-
pact of HCMV infection (24–27). The impact of HCMV-driven
immune differentiation on vaccine responsiveness and efficacy is
therefore still unclear.
The aim of this study, therefore, is to compare NK cell responses
to Ags previously encountered during immunization (Bordetella
pertussis) or during natural infection (H1N1 influenza virus) in
HCMV2 and HCMV+ individuals.
Materials and Methods
Study subjects
Volunteers (n = 152) were recruited from staff and students at the London
School of Hygiene and Tropical Medicine. All subjects gave written
consent and the study was approved by the London School of Hygiene and
Tropical Medicine Ethics Committee. Each subject provided a 50-ml ve-
nous blood sample, and reported vaccination history was recorded. Subject
characteristics are summarized in Table I.
Ab detection by ELISA
Plasma was collected from heparinized whole blood and stored at 280˚C
until use. HCMV infection status was determined by HCMV IgG ELISA
(BioKit). IgG Abs to pertussis toxin (PT; NIBSC) and to formalin-
inactivated whole H1N1 influenza virus (influenza A/California/7/2006
(H1N1)v(NYMC-X179A); H1N1; NIBSC) were determined using in-
house ELISA assays with goat anti-human IgG-peroxidase (Sigma-
Aldrich) as the secondary Ab and SIGMAFAST OPD (Sigma-Aldrich)
as the substrate. IgG concentrations were calculated by interpolation
from a standard curve, which was produced using anti-pertussis reference
serum (NIBSC; IU/ml) or using plasma from a donor with high titers of
Abs to H1N1 influenza (IgG concentration expressed in arbitrary ELISA
units [AEU]) (28). The pooled AB plasma used for in vitro assays con-
tained 6.8 IU/ml IgG to PT and had an H1N1 IgG titer of 273.8 AEU.
PBMC preparation and culture
PBMCs were isolated from heparinized venous blood on a Ficoll–Hypaque
gradient and cryopreserved in liquid nitrogen. Before use, PBMCs were
thawed into complete medium (RPMI 1640 supplemented with 100 U/ml
penicillin/streptomycin and 20 mM L-glutamine [Life Technologies,
Lifesciences] and 10% pooled human AB plasma), washed, and rested for
30 min before use. For some experiments, AB plasma was IgG-depleted
using a protein G-Sepharose column (GE Life Sciences).
PBMCs were cultured for 18 h at 37˚C at 2 3 105/well in 96-well
U-bottom plates (Nunc) in complete medium with or without low concen-
tration of cytokines (LCC; 12.5 pg/ml rhIL-12 [PeproTech] plus 10 ng/ml
rhIL-18 [MBL, Woburn, MA]); high concentration of cytokines (HCC;
5 ng/ml rhIL-12 plus 50 ng/ml rhIL-18); rat anti-IL-2 (3 mg/ml; BD Bio-
sciences); rat IgG2A isotype control (3 mg/ml; BD Biosciences; this was
included in wells with medium alone, as well as Ag alone); 1 mg/ml
formalin-inactivated whole H1N1 influenza virus (NIBSC, as described
earlier); 1 IU/ml killed whole-cell B. pertussis (pertussis; NIBSC); or
MHC class I–deficient K562 target cells (E:T ratio 2:1). GolgiStop (con-
taining Monensin, 1/1500 concentration; BD Biosciences) and GolgiPlug
(containing brefeldin A, 1/1000 final concentration; BD Biosciences) were
added after 15 h. Anti-CD107a Ab (A488-conjugated; BD Biosciences)
was included in the medium for the entirety of cell culture.
For activation via CD16 cross-linking, 96-well flat-bottom plates (Nunc)
were coated with anti-human CD16 (BD Biosciences) or an isotype-matched
control Ab (mIgG1k; BD Biosciences) overnight at 4˚C. Wells were rinsed
with PBS before addition of 23 105 PBMCs/well, which had been incubated
overnight at 37˚C with 50 IU/ml IL-2 (PeproTech). Anti–CD107a-A488 Ab
was added at the beginning of culture, and cells were harvested after 5 h.
Flow cytometry
PBMCs were stained in 96-well U-bottom plates as described previously
(6). In brief, cells were stained with fluorophore-labeled Abs to cell-surface
markers, fixed, permeabilized (Cytofix/Cytoperm; BD Biosciences), and
stained for intracellular molecules. The following mAbs were used: anti–
CD3-V500, anti–CD56-PECy7, anti–IFN-g–allophycocyanin, anti–CD107a-
A488, anti–CD16-allophycocyanin-H7, anti–CD25-allophycocyanin-H7 (all
BD Biosciences), anti–CD57-e450, anti–CD25-PerCPCy5.5, anti–CD16-
allophycocyanin, anti–CD25-PE, anti–IL-18Ra–PE, anti–IL-18Ra–FITC,
anti–IFN-g–allophycocyanin-e780, anti–CD16–allophycocyanin-e780 (all
e-Biosciences), anti–NKG2C-allophycocyanin, anti–NKG2C-PE (both R&D
Systems), and anti–NKG2A-FITC (Miltenyi). IL-12Rb2 Ab was conjugated
using EasyLink PE-Cy5 (Abcam). Cells were acquired on an LSRII flow
cytometer (BD Biosciences) using FACSDiva software. Data analysis was
performed using FlowJo V10 (Tree Star). FACS gates set on unstimulated
cells (medium alone or isotype controls) were applied in standard format
across all samples and all conditions.
NKG2C genotyping
DNA was extracted from whole blood using a Wizard genomic DNA ex-
traction kit (Promega). Donors were then genotyped for NKG2C using
touch-down PCR (Phusion High Fidelity PCR kits; New England Biolabs)
as described previously (29, 30).
Statistical analyses
Statistical analysis of flow cytometry data was performed using Prism 6
(GraphPad), or STATA/IC 13 (StataCorp), as detailed in the figure legends.
Responses where the gated cell subset contained,100 cells were excluded.
Mann–Whitney U tests were used to compare responses between HCMV2
and HCMV+ donors, and linear regression was used to adjust for sex and
age. Unless otherwise stated, statistical tests were one-sided: ****p #
0.0001, ***p , 0.001, **p , 0.01, *p , 0.05.
Results
Donor characterization
Subject characteristics are summarized in Table I. Subjects (n =
152) ranged in age from 20 to 77 y (median = 33 y). Fifty-five
subjects (36.2%) were found to be HCMV seropositive. Anti-
HCMV IgG titer increased significantly with increasing age (R2 =
0.248, p = 0.0001; Supplemental Fig. 1A), but age did not differ
significantly between HCMV+ and HCMV2 donors (two-tailed
Mann–Whitney U test, p = 0.561). Because the proportion of fe-
male and male donors differed between the HCMV2 and HCMV+
groups, subsequent analyses were adjusted for sex.
Cells from all 152 subjects were analyzed for responses to
pertussis. The median anti-PT IgG titer was higher among HCMV2
donors than among HCMV+ donors, but this difference was not
statistically significant (6.7 versus 5.0 IU/ml, two-tailed Mann-
Whitney U test, p = 0.078). One hundred and fourteen donors
(75.0%) confirmed that they had been vaccinated against pertussis,
but a minority of donors reported that they had not been vacci-
nated against pertussis (n = 13; 8.6%) or were unsure of their
vaccination status (n = 25; 16.4%). However, the proportions of
these individuals did not differ between the HCMV+ and HCMV2
groups, and their Ab titers did not suggest a difference in vacci-
nation history (data not shown).
All donors analyzed for responses to vaccine H1N1 influenza
(n = 52) confirmed only natural exposure to H1N1, that is, no pre-
vious seasonal influenza vaccination. Median anti-H1N1 IgG titers
were higher among HCMV2 donors (204.1 AEU/ml) than among
HCMV+ donors (187.2 AEU/ml), although this difference was
not statistically significant (two-tailed Mann–Whitney U test,
p = 0.135).
Ab and Ag-specific IL-2 drive NK cell responses to pertussis
and H1N1 influenza virus
PBMCs from 100 donors were stimulated overnight with pertussis
(Fig. 1B–D), and NK cell responses were measured by flow
cytometry (Fig. 1A). Significant induction of CD25 and IFN-g
(Fig. 1B and 1C) and degranulation (CD107a; Fig. 1D) was ob-
served in response to pertussis. Analysis of this response by
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CD56bright and CD56dim subsets reveals that the CD56dim cells
respond more robustly to pertussis than do the CD56bright NK cells
(and are thus the major contributors to the vaccine response;
Supplemental Fig. 2A–C).
Coexpression of CD25/IFN-g was markedly attenuated in the
presence of a blocking Ab to IL-2 and after depletion of IgG from
the plasma used to supplement the culture medium, indicating
a role for both memory T cell–derived IL-2 and Ag-specific Ab in
the NK cell IFN-g response. By contrast, the degranulation re-
sponse (as measured by cell-surface expression of the lysosomal
marker LAMP-1/CD107a) (31) was dependent upon IgG, but not
IL-2. The observation that neither anti–IL-2 nor IgG depletion
Table I. Donor characteristics
HCMV2 (n = 97) HCMV+ (n = 55)
Median age, y (range) 32 (20–70) 35 (21–77)
Female sex, n (%) 73 (75) 32 (58)
NKG2C genotype +/+, +/2, 2/2, n (%) 67/24/2 (72/26/2) 35/17/2 (65/31/4)
NKG2C2 haplotype frequency (%) 15.0 19.4
Median anti-HCMV IgG titer, IU/ml (range) ,0.25 394.2 (31.1–4411.6)
Median anti-PT IgG titer, IU/ml (range) 6.7 (0.5–139.3) 5.0 (0.8–179.9)
Median anti-H1N1 IgG titer, AEUs (range) 214.6 (80.7–953.2) 190.1 (90.2–522.7)
Donors were classified as HCMV2 and HCMV+ by anti-HCMV IgG ELISA, using 0.25 IU/ml as the cutoff per manufacturer’s instructions. NKG2
genotype (NKG2C+/+, NKG2C+/2, NKG2C2/2) was determined by PCR. IgG Ab titers against PT and H1N1 were calculated from interpolation of
a reference serum or high-titer donor standard curve, respectively.
FIGURE 1. NK cell responses to pertussis and H1N1 are inhibited by IL-2 neutralization and IgG depletion. PBMCs were cultured in vitro for 18 h with
medium alone, killed whole-cell pertussis (Per), and inactivated whole H1N1 influenza virus (H1N1), pertussis or H1N1 with blocking Ab to IL-2 (Per
a-IL-2, H1N1 a-IL-2), or pertussis or H1N1 in IgG-depleted plasma (Per IgG depl., H1N1 IgG depl.). The isotype control Ab (IgG2A) for the IL-2
blocking Ab was included in the medium, pertussis, and H1N1 wells. Representative flow cytometry plots show gating of CD32CD56+ NK cells and
expression of CD25, IFN-g, and CD107a (A). Responses to pertussis (B–D) and H1N1 (E–G) were measured by the percentage of NK cells expressing
CD25 (B and E), coexpressing CD25/IFN-g (C and F), and expressing CD107a (D and G). Data were analyzed in Prism using paired, one-tailed Wilcoxon
signed-rank tests. Each data point represents one donor, n = 100 (B–D) or n = 16 (E–G), and bar graphs denote medians. ****p # 0.0001, ***p , 0.001,
**p , 0.01, *p , 0.05.
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completely abrogated the NK cell IFN-g response suggests that
these two signals may synergize for optimal IFN-g production.
Cells from a subset of subjects (n = 16) were also analyzed for
responses to H1N1 influenza in the context of IL-2 blockade or
IgG depletion (Fig. 1E–G). As observed with pertussis, statisti-
cally significant induction of CD25 (Fig. 1E), CD25/IFN-g (Fig. 1F),
and CD107a (Fig. 1G) was observed in response to restimulation
with H1N1 Ag, and IL-2 blocking significantly decreased CD25/
IFN-g expression (Fig. 1F), whereas IgG depletion inhibited the
degranulation (CD107a) response (Fig. 1G). Interestingly, and
in contrast with the response to pertussis, IgG depletion enhanced
IFN-g production in response to H1N1, and IL-2 blockade slightly
decreased degranulation, indicating competition between these
pathways for NK cell activation during influenza responses
(Fig. 1F).
HCMV infection is associated with impaired NK cell responses
to pertussis and H1N1 influenza virus
NK cell responses to pertussis (n = 152) and H1N1 (n = 52) were
compared between HCMV2 and HCMV+ donors (Fig. 2). Con-
sistent with prior observations (3, 6), responses to pertussis and
H1N1 were significantly augmented by LCC IL-12 and IL-18 (p #
0.0001 for all parameters), indicating that in vitro accessory cell
activation and production of IL-12 and IL-18 (which is essential
for IL-2–mediated NK cell activation) (3, 5, 32) were suboptimal.
Interestingly, in the absence of LCC, pertussis induces stronger
NK cell responses than H1NI, whereas in the presence of LCC,
H1N1 induces the most robust responses. This may indicate that
pertussis induces some IL-12 and IL-18 (such that LCC is re-
dundant in these assays), whereas H1N1 may be a poor inducer of
IL-12 and IL-18 but a better inducer of IL-2 or other accessory
cytokines. This would be consistent with differences in TLR
signaling by RNA viruses such as influenza (TLR3) and Gram-
negative bacteria such as pertussis (TLR4) (33–36).
NK cells from both HCMV+ and HCMV2 donors responded to
pertussis and H1N1 (with or without LCC; Fig. 2); however, NK
cell responses to these two vaccines (whether defined as CD25+,
CD25+IFN-g+, or CD107a+) were significantly lower among
HCMV+ donors than among HCMV2 donors (Fig. 2A and 2B).
This was true for both vaccines and all parameters when cells
were cultured with LCC, and was also true for the CD25+ and
CD25+IFN-g+ responses to H1N1 and the CD25+ and CD107a+
responses to pertussis in the absence of LCC. Importantly, resting
levels of CD25 expression did not differ significantly between
HCMV+ and HCMV2 donors (Fig. 2A), and there was no dif-
ference in the potential of T cells from HCMV2 and HCMV+
donors to produce IL-2 in response to pertussis Ag (Supplemental
Fig. 1B and 1C). Furthermore, there is no intrinsic difference in
the ability of NK cells from HCMV+ and HCMV2 donors to
degranulate in response to CD16 cross-linking or K562 stimula-
tion (Supplemental Fig. 1D and 1E). However, NK cell CD25+,
CD25+IFN-g+, and CD107a+ expression in response to HCC (high
concentrations of IL-12 and IL-18) were all significantly higher in
HCMV2 compared with HCMV+ donors (Fig. 2A–C). Analysis of
FIGURE 2. NK cell responses to vaccine Ag are affected by HCMV infection. PBMCs were cultured in vitro for 18 h with medium alone, LCC, killed
whole-cell pertussis (Per), inactivated whole H1N1 influenza virus (H1N1), Per + LCC, H1N1 + LCC, or HCC. Donors were stratified into HCMV2 (2)
and HCMV+ (+) groups. Responses were measured as the percentage of NK cells expressing CD25 (A), coexpressing CD25/IFN-g (B) or CD107a (C).
Bivariate regression of age against responses to Per + LCC was performed for the percentage of NK cells expressing CD25 (D), CD25/IFN-g (E), and
CD107a (F). Each data point represents one donor, n = 152, except for H1N1 and H1N1 + LCC where n = 52. Bar graphs denote medians. NB, all Ag
stimulations induced statistically significant increases in expression of CD25, CD25/IFN-g, and CD107a over background (medium alone for pertussis/
H1N1, or LCC for pertussis+LCC/H1N1+LCC; p , 0.05 in all cases), except that H1N1 did not induce a significant increase in CD25+IFN-g+ NK cells in
HCMV+ donors (p = 0.416). Data were analyzed in Prism using, one-tailed Mann–Whitney U tests. ****p# 0.0001, ***p, 0.001, **p, 0.01, *p, 0.05.
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this response by CD56bright and CD56dim subsets reveals that the
effect of HCMV status is due entirely to an effect within the
CD56dim subset (Supplemental Fig. 2D–F).
In addition to consistently lower NK cell responses to vaccine
Ags in HCMV+ individuals, there was a trend for CD25 and CD25/
IFN-g responses to pertussis (with or without LCC) to decline
with increasing age (Fig. 2D and 2E). This was statistically sig-
nificant for the cohort as a whole (CD25+ pertussis: R2 = 0.0549,
p = 0.0052; CD25+ pertussis + LCC: R2 = 0.0453, p = 0.0122;
CD25+IFN-g+ pertussis: R2 = 0.0379, p = 0.0203; CD25+IFN-g+
pertussis + LCC: R2 = 0.0478, p = 0.0095), but not when analyzed
separately for HCMV2 and HCMV+ donors due to decreased
power. There was no effect of age on CD107a expression (per-
tussis: R2 = 0.00491, p = 0.4089; pertussis + LCC: R2 = 0.00879,
p = 0.272; Fig. 2F), which is consistent with maturation of the
NK cell repertoire, and therefore decreased sensitivity to exoge-
nous cytokines, but maintained cytotoxicity, during normal aging
(reviewed in Ref. 37) and increasing NK cell differentiation (8, 9).
Importantly, the effect of HCMV infection on impaired NK cell
responses to pertussis and H1N1 is entirely independent of the
association between age and NK cell function. In line with this
conclusion, adjusting for age by parametric regression did not
alter the conclusions of the study (Table II).
Overall, NK cell responses did not differ significantly between
males and females, although there was a trend for median responses
to be higher in women than in men, and this reached statistical
significance (p , 0.05) for the IFN-g response to pertussis + LCC
in HCMV+ donors (data not shown). Because the proportion of
female subjects differed between the HCMV2 and HCMV+
groups (Table I), the data in Fig. 2 were reanalyzed, adjusting for
sex, as well as age, using parametric regression (Table II). After
adjustment, CD25/IFN-g and CD107a expression in response to
vaccine alone (i.e., without LCC) are no longer significantly dif-
ferent between HCMV2 and HCMV+ donors, but responses to
vaccine with LCC, and responses to HCC, remain significantly
lower in HCMV+ compared with HCMV2 donors.
Finally, no associations were observed between anti-HCMV
titer and any NK cell responses among the HCMV+ subjects, and
there was no effect of NKG2C genotype (which may affect NK
cell differentiation) (30, 38, 39) on NK cell responses (data not
shown).
NK cell differentiation only partially explains reduced
responses to vaccines in HCMV+ donors
We hypothesized that reduced cytokine-mediated NK cell re-
sponses among HCMV+ donors would reflect expansion of the
highly differentiated CD56dimCD57+NKG2C+ NK cell subset,
which is known to be hyporesponsive to cytokines (12). Indeed, ex
vivo analysis confirmed observations from previous studies that
HCMV+ donors had lower proportions of CD56dimCD572 NK
cells and higher proportions of CD56dimCD57+ NK cells than did
HCMV2 donors (Fig. 3A and 3B); there was no difference be-
tween the groups in the proportion of cells with intermediate
CD57 expression (CD56dimCD57int, gating shown in Fig. 3A).
Consistent with previous work (10–12, 16, 17), HCMV seropos-
itivity was also associated with a higher proportion of CD16+
(Fig. 3C) and NKG2C+ (Fig. 3D) cells, and a lower proportion of
NKG2A+ cells (Fig. 3E), within the total NK cell population.
Moreover, HCMV seropositivity was correlated with a lower
proportion of CD572NKG2C2 cells and a higher proportion of
CD57+NKG2C+ cells within the CD56dim NK cell population
(Fig. 3F).
Although the increased proportion of CD56dimCD57+ NK cells
among HCMV+ donors likely contributes to their reduced re-
sponsiveness to cytokines, we also observed significantly reduced
CD25, CD25/IFN-g, and CD107a expression in response to both
pertussis and H1N1 within individual NK cell subsets. This was
especially evident among CD56dimCD57+ cells and for cultures
containing LCC (Fig. 4A–F), but this was also the case for cul-
tures stimulated with vaccine alone (Supplemental Fig. 3G–I and
3M–O).
Similarly, when cells were grouped by expression of CD57 and
NKG2C, we found that responses to pertussis with LCC were lower
among NKG2C+ NK cells than among NKG2C2 cells (Fig. 4G–I).
This association was statistically significant for CD57+ NK cells
of HCMV+ donors, but evaluation of the HCMV2 cohort lacked
statistical power as too few donors had sufficient NKG2C+ cells to
allow a robust analysis. Interestingly, however, responses of all
Table II. NK cell responses to vaccine Ags by HCMV status after adjusting for sex and age
Adjusted for Sex and Age
Stimulus Parameter (Total NK Cells) Effect (95% CI)a pb
Pertussis CD25+ 24.4 (28.3, 20.5) 0.014
CD25+IFN-g+ 20.5 (21.2, 0.3) 0.125
CD107a+ 21.5 (23.4, 0.5) 0.071
Pertussis + LCC CD25+ 28.5 (213.7, 23.4) 0.001
CD25+IFN-g+ 21.5 (22.8, 20.1) 0.020
CD107a+ 22.9 (25.5, 20.3) 0.016
H1N1 CD25+ 25.4 (29.5, 21.3) 0.005
CD25+IFN-g+ 20.4 (21.1, 0.4) 0.158
CD107a+ 21.8 (23.9, 0.3) 0.049
H1N1 + LCC CD25+ 212.2 (222.6, 21.8) 0.011
CD25+IFN-g+ 25.1 (210.4, 0.1) 0.027
CD107a+ 25.1 (28.9, 21.5) 0.004
HCC CD25+ 211.3 (216.7, 26.0) ,0.0001
CD25+IFN-g+ 26.5 (211.4, 21.7) 0.005
CD107a+ 22.1 (23.5, 20.6) 0.004
A regression analysis was performed in STATA to adjust for sex and age when comparing NK cell responses to pertussis (2/+ LCC), H1N1 (2/+ LCC),
and HCC between HCMV2 and HCMV+ donors. The response was quantified by the percentage of total NK cells expressing CD25, CD25/IFN-g
(CD25+IFN-g+), and CD107a.
aEffect (coefficient), with 95% confidence interval (CI), represents the change in the mean percentage of NK cells responding in HCMV+ donors as
compared with HCMV2 donors.
bThe p value refers to the significance of the difference in response between HCMV2 and HCMV+ donors after adjusting for sex and age. The
p values , 0.05 are underlined.
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four subsets were significantly lower among HCMV+ donors than
among HCMV2 donors (Fig. 4G–I), despite minimal differences
in responses to LCC alone (Supplemental Fig. 3A–F). These data
indicate that the reduced response of HCMV+ donors reflects
differences in the intrinsic responsiveness of NK cells within
a subset, as well as differences in the distribution of these subsets.
Although the level of expression (median fluorescence intensity
[MFI]) of both CD57 and NKG2C was higher on CD56dimCD57+
NK cells in HCMV+ donors compared with HCMV2 donors
(median MFI CD57: 13,526 versus 10,575, p = 0.0032; median
MFI NKG2C: 141 versus 80.9, p , 0.0001, data not shown), there
was no significant association between CD57 and NKG2C ex-
pression levels and NK cell responsiveness in HCMV+ donors
(data not shown).
Because only some HCMV+ individuals have obvious expansion
of the CD56dimCD57+NKG2C+ subset, we considered whether
NK responses might differ between HCMV+ individuals with and
without this expanded population. Sixteen of 55 (29%) HCMV+
donors demonstrated expansion of the CD56dimCD57+NKG2C+
subset (defined as % CD56dimCD57+NKG2C+ cells greater than
the mean + 3 SD of that in HCMV2 donors), and NK cells from
these donors tended to respond less robustly than did cells from
HCMV+ donors without this expansion (Fig. 5). Importantly, there
was evidence by trend analysis for decreasing NK cell respon-
siveness with HCMV infection and then with HCMV infection
plus expansion of the CD56dimCD57+NKG2C+ subset (Fig. 5).
This confirms that although expansion of the CD56dimCD57+
NKG2C+ subset is associated with loss of NK cell responsiveness
in vaccine recall assays, cells of HCMV+ donors respond less well
than do cells of HCMV2 donors, irrespective of NKG2C ex-
pression.
HCMV infection is associated with altered expression of
cytokine receptors by NK cells
Although there was a clear role for specific IgG in induction of
CD25, CD25/IFN-g, and CD107a expression (Fig. 1), impairment
of CD16-mediated signaling seemed an unlikely explanation for
reduced NK cell responsiveness because HCMV+ individuals have
a higher frequency of CD16+ NK cells (Fig. 3C), cells from
HCMV+ and HCMV2 donors responded equally well to CD16
cross-linking (Supplemental Fig. 1D), and use of pooled AB
plasma for in vitro assays ensured that specific IgG concentrations
were consistent in all assays.
In contrast, differences between HCMV+ and HCMV2 donors
were most marked in cultures containing LCC (Fig. 2) and in
cultures with high concentrations of the cytokines IL-12 and IL-18
(HCC; Fig. 6A–C), suggesting that differences in expression of
cytokine receptors might explain our observations. Although there
FIGURE 3. Comparison of ex vivo expression of NK cell markers and receptors in HCMV2 and HCMV+ donors. PBMCs were analyzed ex vivo for
surface expression of CD56, CD57, CD16, NKG2C, and NKG2A, as shown by representative flow cytometry plots (A). Proportions of total NK cells in the
CD56bright, CD56dimCD572, CD56dimCD57int, and CD56dimCD57+ subsets were compared between HCMV2 and HCMV+ donors (B), as was expression of
CD16 (C), NKG2C (D), NKG2A (E), and CD57/NKG2C (F, CD56dim only). The percentages of cells expressing each marker in HCMV2 (2) and HCMV+
(+) donors were compared using two-tailed Mann–Whitney U tests. Each data point represents one donor, n = 152; bar graphs denote medians. ****p #
0.0001, ***p , 0.001, **p , 0.01, *p , 0.05.
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was no difference in resting (ex vivo) expression of IL-12Rb2 on
any NK cell subset (Fig. 6D and 6E), IL-12Rb2 was significantly
upregulated on the total NK cell population in HCMV2 but not
from HCMV+ donors after culture with HCC (Fig. 6F). Moreover,
and consistent with data showing associations between acquisition
of CD57 and decreased IL-18Ra expression (6, 8, 9), resting NK
cells from HCMV+ donors were significantly less likely than cells
from HCMV2 donors to express IL-18Ra, and this difference was
especially marked in the (expanded) CD56dimCD57+ NK cell
subset (Fig. 6G and 6H).
Discussion
During secondary immune responses, both CD4+ T cell–derived
IL-2 and Ag–Ab immune complexes induce “Ag-specific” NK cell
activation, allowing NK cells to act as effectors of the adaptive
immune response and to contribute to postvaccination immunity
by secretion of IFN-g and/or by cytotoxicity (3–6, 14). In this
study, we demonstrate for the first time, to our knowledge, that the
contribution of NK cells to adaptive immune responses is affected
by HCMV infection: NK cells from HCMV+ donors respond
significantly less well than cells from HCMV2 donors to killed
whole-cell pertussis or inactivated whole H1N1 influenza virus.
The effect of HCMV infection on NK cell responsiveness is in-
dependent of age, sex, or anti-HCMV IgG titer.
Our data also demonstrate for the first time, to our knowledge,
that there is an additive effect between the cytokine and the IgG
pathways driving NK cell IFN-g production, because both IgG
depletion and IL-2 blockade reduced NK cell IFN-g responses in
response to stimulation of PBMCs with pertussis vaccine. Of
particular interest, IgG depletion markedly reduced Ag-induced
CD25 expression on NK cells. We propose that CD16 cross-
linking by immune complexes upregulates CD25 expression, in-
creasing sensitivity to T cell–derived IL-2, and thereby enhancing
IFN-g production. However, CD16 cross-linking is not essential
for upregulation of CD25, because this can be induced by Ag
alone, presumably in response to IL-12 and IL-18 produced by
APCs (6, 40–42). Release of cytotoxic granules, as measured
by upregulation of CD107a on the cell surface, is also inhibited by
IgG depletion but is unaffected by IL-2 blockade, suggesting that
NK cells could act as effectors of the adaptive response through
ADCC in the absence of memory T cells, providing there is suf-
ficient circulating Ab.
However, whereas IgG depletion also decreased H1N1-induced
CD25 expression on NK cells, H1N1 induction of IFN-g was
FIGURE 4. HCMV infection affects vaccine Ag responses of all NK cells, irrespective of their differentiation status. PBMCs were cultured in vitro for
18 h with killed whole-cell pertussis with LCC (pertussis + LCC) (A–C and G–I) or inactivated whole H1N1 influenza virus with LCC (H1N1 + LCC) (D–
F). Responses were measured as the percentage of cells expressing CD25 (A, D, and G), CD25/IFN-g (B, E, and H), and CD107a (C, F, and I) by CD56/
CD57-defined subsets (A–F) or CD56dim CD57/NKG2C-defined subsets (G–I) and compared between HCMV2 (2) and HCMV+ donors (+). Data were
analyzed using one-tailed Mann–Whitney U tests. Each data point represents one donor, n = 152 (A–C and G–I) or n = 52 (D–F); bar graphs denote medians.
NB, for CD57/NKG2C-defined subsets, CD57int cells were grouped together with CD572 cells. ****p # 0.0001, ***p , 0.001, **p , 0.01, *p , 0.05.
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significantly enhanced in the absence of IgG. We have observed that
individual NK cells tend to either produce IFN-g or degranulate
(but not both; unpublished data), suggesting that inhibiting the de-
granulation response to H1N1 by removing IgG skews the response
toward IFN-g production. However, given the limited effect of IgG
depletion on H1N1-induced degranulation, it is unclear why this
should be the case. Indeed, expression of CD107a in response to
H1N1 seems to be relatively unaffected by either IL-2 blockade or
IgG depletion. This suggests that H1N1-driven degranulation may
be affected by other stimuli, such as type I IFNs (43, 44).
We had hypothesized that decreased responses to vaccines in
HCMV+ donors would be attributable to a redistribution of the
NK cell repertoire. HCMV infection drives the expansion of a
CD56dimCD57+NKG2C+ subset of NK cells (11, 16, 17, 45),
which display a highly differentiated phenotype, including re-
duced responsiveness to exogenous cytokine stimulation (8, 9) and
epigenetic changes at the IFNG locus (46). These phenotypic and
functional changes are similar to those observed during aging (15,
47), and comparisons have been drawn between the effects of
HCMV and immunosenescence (48). Because our previous work
has indicated that NK cell IFN-g production after restimulation
with vaccine Ags is cytokine dependent (3), we predicted that
fewer NK cells from HCMV+ donors would produce IFN-g in
response to pertussis or influenza Ags because of the reduced
capacity of the expanded CD56dimCD57+NKG2C+ subset to re-
spond to cytokines. Ex vivo analyses confirmed that HCMV+
donors had higher proportions of CD56dimCD57+ and CD56dim
CD57+NKG2C+ NK cells than did HCMV2 donors, and func-
tional analysis confirmed that few of the highly differentiated
CD57+ NK cells produced IFN-g after Ag stimulation. Interest-
ingly, however, our data also show that, irrespective of their CD57/
NKG2C surface phenotype, NK cells from HCMV+ donors are
less likely to produce IFN-g in response to vaccines than are cells
from HCMV2 donors. In other words, there are pronounced
functional differences between HCMV+ and HCMV2 donors
within NK cell subsets. The reduced NK cell IFN-g response to
vaccine Ags in HCMV+ donors is therefore not simply due to
expansion of the CD56dimCD57+NKG2C+ subset. Although ac-
quisition of NKG2C was functionally relevant (associated with
reduced IFN-g and degranulation responses), it was not sufficient
to explain the reduced responsiveness of cells from HCMV+
donors.
FIGURE 5. NK cell responses of HCMV+ donors with or without the characteristic CD56dimCD57+NKG2C+ expansion. PBMCs were cultured in vitro
for 18 h with medium alone, LCC, killed whole-cell pertussis (Per), inactivated whole H1N1 influenza virus (H1N1), Per + LCC, H1N1 + LCC, or HCC.
Donors were stratified into HCMV2 (2), HCMV+ without expansion of CD56dimCD57+NKG2C+ cells (+), and HCMV+ with expansion of CD56dimCD57+
NKG2C+ cells (++). Responses are expressed as the percentage of total NK cells expressing CD25 (A), coexpressing CD25/IFN-g (B), or expressing
CD107a (C). CD57-defined (D–F) or CD57/NKG2C-defined subsets (G–I) were analyzed for responses to pertussis with LCC for CD25 (D and G), CD25/
IFN-g (E and H), and CD107a (F and I). Data were analyzed in Prism using one-tailed Mann–Whitney U tests to compare responses between HCMV+
donors and either HCMV2 donors or HCMV++ donors. ANOVA for linear trend (from 2 to + to ++) was also performed for each functional readout. Each
data point represents one donor, n = 152, except for H1N1 and H1N1 + LCC where n = 52. Bar graphs denote medians. ****p # 0.0001, ***p , 0.001,
**p , 0.01, *p , 0.05.
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Although further studies are required to define the “within
subset” effects of HCMV infection, our data suggest that reduced
expression of IL-18Ra or reduced ability to upregulate IL-12Rb2
among NK cells from HCMV-infected individuals may partially
explain their failure to produce IFN-g. Although decreasing ex-
pression of IL-12Rb2 and IL-18Ra has been associated with
CD57 expression, this is the first demonstration, to our knowledge,
that there are differences in cytokine receptor expression between
HCMV+ and HCMV2 donors and it is possible to see how each of
these might affect NK cell responses. Higher resting levels of IL-
18Ra expression would increase the sensitivity of NK cells to low
concentrations of IL-18 being produced by APCs in response to
innate receptor ligands in whole-cell pertussis or inactivated in-
fluenza virus. IL-18 signaling upregulates CD25 (49), thereby
increasing sensitivity to IL-2. IL-2 signaling might then upregulate
IL-12R2b (50, 51), allowing IL-12 to synergize with IL-2 to drive
IFN-g production (3, 40, 52), while also generating a positive
feedback loop in which IL-12 signaling upregulates IL-18Ra (53,
54), IL-18 signaling, and CD25. However, although cytokine re-
ceptor expression is likely to play a role in determining NK cell
responsiveness to vaccine Ags in HCMV2 and HCMV+ donors,
the biological relevance of small changes in surface expression on
IL-12Rb2 needs to be demonstrated. Moreover, although we have
no evidence to suggest that T cell IL-2 production in response to
vaccine Ags is affected by HCMV infection, future studies will
need to determine the extent to which concomitant changes in
APC function during HCMV infection also affect NK cell re-
sponses.
We had initially considered NK cell degranulation during vac-
cine restimulation to be a result of CD16 cross-linking by IgG
immune complexes, as suggested by the IgG depletion data and
accepted models of ADCC. The expectation was, therefore, that
although IFN-g responses might be impaired, NK cell degranu-
lation responses would be sustained in HCMV+ donors. Indeed,
cross-linking with anti-CD16 Ab induced equivalent levels of
CD107a upregulation. It was, therefore, somewhat surprising that
degranulation responses to vaccine were lower in HCMV+ donors
than in HCMV2 donors. However, degranulation responses to
HCC were also lower in HCMV+ donors, supporting the notion of
synergy between the cytokine and CD16 pathways, and adding
FIGURE 6. Decreased cytokine responsiveness and decreased cytokine receptor expression by NK cells from HCMV+ donors. (A–C) PBMCs were
cultured in vitro for 18 h with an HCC. Responses were measured as the percentage of CD56dim CD57/NKG2C-defined cells expressing CD25 (A), CD25/
IFN-g (B), and CD107a (C), and compared between HCMV2 (2) and HCMV+ donors (+). (D–F) NK cells were analyzed for surface expression of IL-
12Rb2 using an mIgG1 PECy5-conjugated isotype control to set the gate (D). Total NK cells (E and F) and CD56/CD57-defined subsets (E) were analyzed
ex vivo (E) and after 18 h culture in vitro with LCC or HCC (F). (G and H) NK cells were also analyzed for IL-18Ra surface expression using the T cell
population to set the IL-18Ra gate (G), for total NK cells and CD56/CD57-defined subsets ex vivo (H). HCMV2 and HCMV+ donors were compared using
one-tailed (A–C) or two-tailed (E, F, and H) Mann–Whitney U tests. Each point represents one donor, n = 152 (A–C, E, and H) or n = 16 (F); bar graphs
denote medians. ****p # 0.0001, **p , 0.01, *p , 0.05.
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weight to the suggestion that HCMV infection may affect cytokine
receptor expression.
Our findings have potentially important implications. HCMV
infection is a known risk factor for all-cause mortality in adults
(55), and perinatal HCMV infection is associated with slower
growth and increased rates of hospitalization in African children
(56). The underlying biology of these relationships is unknown,
but reduced responsiveness to vaccination or reduced resilience in
the face of infection are plausible explanations. Distorted T cell
and NK cell phenotypes in HCMV+ individuals have been widely
reported (15, 57–59), giving credence to the possibility that
adaptive immune responses may be less effective in infected
individuals. Further work will need to address the clinical con-
sequences of altered NK cell responses to infection and vaccina-
tion in HCMV-infected individuals.
To our knowledge, this is the first published study of the effect
of HCMV infection on NK cell responses to vaccine Ags. When
compared with the marked effect of HCMVon cellular immune
responses in our adult cohort, the modest phenotype seen in the
infant studies (24, 25) raises the intriguing question whether the
duration of HCMV infection affects vaccine responses. We have
previously shown in an African population that, with near-universal
infant HCMV infection, the characteristic “adult HCMV” NK
cell profile is reached by early adolescence (30). The majority of
our donors are of European or North American origin (data not
shown), suggesting that they may have been infected in ado-
lescence or adulthood (60, 61), potentially explaining some of
the heterogeneity in the responses we see within the HCMV+ group.
Similarly, there will be variation among our donors in time since
vaccination (pertussis) or infection (H1N1), and it is likely that
relatively low IFN-g responses we observe in comparison with
earlier studies (3) is due to the much longer interval between pri-
mary and secondary exposures to Ag. Future studies will need
to assess whether the duration of HCMV infection is a risk factor
for altered NK responses and whether this manifests itself as re-
duced responsiveness to active vaccination and reduced vaccine
efficacy.
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